# Marksans Pharma Ltd (MARKSANS)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹216.17
Day Change: -0.57%
52W High: ₹270.7
52W Low: ₹155
Market Cap: ₹9,862 Cr

## Valuation
P/E: 27.37
P/B: 3.67
EPS: ₹7.95
Book Value: ₹59.37
Dividend Yield: 0%

## Returns
1Y Return: 10.69%

## Profitability
ROE: 0%
ROCE: 35.23%
Debt/Equity: 0.12
Revenue Growth: 10.6%
Profit Growth: 8.2%
EBITDA Margin: 17.56%
Operating Margin: 18.08%

## About
Marksans Pharma Ltd is a Drug Manufacturers - General company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - General
Sub Industry: Unknown

## Business Model
Overview: Marksans Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - General. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Quarterly Report: Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results And To Consider Recommendation Of Dividend If Any, For The Financial Year Ended March 31, 2026
- Announcement: Compliances-Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations, 2018
- BSE Filing: Compliances-Certificate Under Reg. 74 (5) Of SEBI (DP) Regulations, 2018

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:03.547Z
Price History Updated: 2026-05-18T22:58:27.545Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:27.545Z
Quant Updated: 2026-05-18T22:58:27.545Z
Sentiment Updated: 2026-05-18T22:58:27.545Z
Financials Status: current
Financials Updated: 2026-05-18T11:30:48.172Z
Financials Last Attempt: 2026-05-18T11:30:48.172Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹630 Cr
Operating Profit: ₹118 Cr (OPM 19%)
Net Profit: ₹74 Cr
Tax: ₹86 Cr

## Annual P&L History
Mar 2015: Rev ₹630Cr | PAT ₹74Cr | OPM 19%
Mar 2016: Rev ₹797Cr | PAT ₹112Cr | OPM 23%
Mar 2017: Rev ₹893Cr | PAT ₹83Cr | OPM 15%

## Balance Sheet (Mar 2015)
Total Assets: ₹490 Cr
Total Liabilities: ₹490 Cr
Borrowings: ₹173 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Mark B. Saldanha, Non-Independent Executive Chairman & MD
- Jitendra M. Sharma, Group Chief Financial Officer
- Harshavardhan  Panigrahi, Company Secretary, Manager of Legal & Compliance Officer
- Sandra  Saldanha, Whole-Time Executive Non Independent Director
- Varddhman Vikramaditya Jain, Whole-Time Executive Non Independent Director

---
Source: rupiya.io/stocks/marksans
Disclaimer: For research and education only. Not investment advice.